Key statistics
As of last trade, Immunitybio Inc (IBRX:NSQ) traded at 5.01, 61.61% above the 52 week low of 3.10 set on Dec 11, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.04 |
---|---|
High | 5.07 |
Low | 4.96 |
Bid | 5.01 |
Offer | 5.02 |
Previous close | 5.04 |
Average volume | 5.22m |
---|---|
Shares outstanding | 696.53m |
Free float | 159.61m |
P/E (TTM) | -- |
Market cap | 3.51bn USD |
EPS (TTM) | -0.867 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 14:56 GMT.
More ▼
- ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
- ImmunityBio Reports Third-Quarter 2024 Financial Results
- First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
- ImmunityBio to Participate in the Jefferies London Healthcare Conference
- ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
More ▼